Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity

Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE...

Full description

Saved in:
Bibliographic Details
Published in:Mediators of inflammation 2020, Vol.2020 (2020), p.1-8
Main Authors: Wang, Guochun, Li, Sizhao, Ge, Yongpeng, Liu, Xia, Shu, Xiaoming, He, Linrong, Lu, Xin
Format: Article
Language:English
Subjects:
Adult
Age
Arthritis, Rheumatoid - blood
Autoimmune diseases
Autoimmune Diseases - blood
Biomarkers - blood
Blood tests
Clinical medicine
Comparative analysis
Dermatomyositis
Dermatomyositis - blood
Dermatomyositis - pathology
Disease
Electronic medical records
Ferritin
Humans
Inflammation
Inflammatory diseases
Interleukin 2
Interleukin 2 receptors
Interleukins
Laboratories
Lymphocytes
Lymphocytes T
Male
Medical prognosis
Middle Aged
Musculoskeletal diseases
Myopathy
Myositis
Pathogenesis
Patients
Receptors, Interleukin-2 - blood
Rheumatoid arthritis
Rheumatoid factor
Skin
Skin diseases
Skin lesions
Skin Ulcer - blood
Skin Ulcer - pathology
Somatotropin
Studies
Systemic lupus erythematosus
T cells
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833
cites cdi_FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833
container_end_page 8
container_issue 2020
container_start_page 1
container_title Mediators of inflammation
container_volume 2020
creator Wang, Guochun
Li, Sizhao
Ge, Yongpeng
Liu, Xia
Shu, Xiaoming
He, Linrong
Lu, Xin
description Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P
doi_str_mv 10.1155/2020/6243019
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0acac352b35f4d8cb23cbcd72ae608b7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639994285</galeid><doaj_id>oai_doaj_org_article_0acac352b35f4d8cb23cbcd72ae608b7</doaj_id><sourcerecordid>A639994285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833</originalsourceid><addsrcrecordid>eNqNkktvEzEURkcIRENhxxqNxAYJpvVr_GCBFLU8IkVConRtPJ47icPMONhOq_x7HBJaglggLyzZ5x7rXn9F8RyjM4zr-pwggs45YRRh9aCYYMZ5hSXHD4sJUpxUitb4pHgS4wohVDMmHxcnlAjBMBOT4tuV7zdND-VsXpHyC1hYJx9KN5aXEAaT_LD10SUX35azFMtpjN46k5wfY3nr0rK8-p7Z695CiKUZ2_LSRTARyqlN7sal7dPiUWf6CM8O-2lx_eH914tP1fzzx9nFdF5ZjliqAHGDOioVkkopENBQ2cmGCsJwg6zFiDegQNqWdVbVDTHGMpwpLLiwktLTYrb3tt6s9Dq4wYSt9sbpXwc-LLQJydkeNDLWWFqThtYda6VtCLWNbQUxwJFsRHa927vWm2aA1sKYgumPpMc3o1vqhb_RgiGBMMuCVwdB8D82EJMeXLTQ92YEv4k6_xaRXCBWZ_TlX-jKb8KYR7WjsGCqrsU9tTC5ATd2Pr9rd1I95TRPjBG5c539g8qrhcFZP0Ln8vlRwZt9gQ0-xgDdXY8Y6V269C5d-pCujL_4cy538O84ZeD1Hli6sTW37j91kBnozD2NFZaC0Z9yQ9-M</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2431749557</pqid></control><display><type>article</type><title>Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>NCBI_PubMed Central（免费）</source><source>ProQuest - Publicly Available Content Database</source><creator>Wang, Guochun ; Li, Sizhao ; Ge, Yongpeng ; Liu, Xia ; Shu, Xiaoming ; He, Linrong ; Lu, Xin</creator><contributor>Guan, Qingdong ; Qingdong Guan</contributor><creatorcontrib>Wang, Guochun ; Li, Sizhao ; Ge, Yongpeng ; Liu, Xia ; Shu, Xiaoming ; He, Linrong ; Lu, Xin ; Guan, Qingdong ; Qingdong Guan</creatorcontrib><description>Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P&lt;0.001), while there was no significant difference between IMNM and HCs. There were also no significant differences of sIL-2R levels in DM, SLE, and RA. Importantly, serum sIL-2R levels were significantly higher in treatment-naïve or active DM patients than those that are not (1100.9±550.4 U/ml vs. 615.6±330.4 U/ml, P=0.006; 808.8±421.6 U/ml vs. 339.8±103.4 U/ml, P&lt;0.001). DM patients with skin ulcers had significantly higher sIL-2R levels than those without (889.3±509.9 U/ml vs. 640.0±368.7 U/ml, P=0.023). Cross-sectional analysis in DM showed that sIL-2R levels positively correlated with CK, ESR, CRP, ferritin, physician VAS, and MYOACT scores (rho=0.278, rho=0.474, rho=0.469, rho=0.454, r=0.646, and r=0.600, respectively; all P&lt;0.05), negatively correlated with T cell counts and MMT8 scores (r=−0.380, P=0.002; rho=−0.394, P=0.001). Follow-up study showed that changes in sIL-2R levels after treatment correlated with changes in physician VAS and MYOACT scores (r=0.823 and r=0.695, respectively; all P&lt;0.01). Conclusion. Serum sIL-2R levels were elevated in DM but not in IMNM. Serum sIL-2R could act as a disease activity marker and be associated with ulcerative skin lesions in DM.</description><identifier>ISSN: 0962-9351</identifier><identifier>EISSN: 1466-1861</identifier><identifier>DOI: 10.1155/2020/6243019</identifier><identifier>PMID: 32774147</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Age ; Arthritis, Rheumatoid - blood ; Autoimmune diseases ; Autoimmune Diseases - blood ; Biomarkers - blood ; Blood tests ; Clinical medicine ; Comparative analysis ; Dermatomyositis ; Dermatomyositis - blood ; Dermatomyositis - pathology ; Disease ; Electronic medical records ; Ferritin ; Humans ; Inflammation ; Inflammatory diseases ; Interleukin 2 ; Interleukin 2 receptors ; Interleukins ; Laboratories ; Lymphocytes ; Lymphocytes T ; Male ; Medical prognosis ; Middle Aged ; Musculoskeletal diseases ; Myopathy ; Myositis ; Pathogenesis ; Patients ; Receptors, Interleukin-2 - blood ; Rheumatoid arthritis ; Rheumatoid factor ; Skin ; Skin diseases ; Skin lesions ; Skin Ulcer - blood ; Skin Ulcer - pathology ; Somatotropin ; Studies ; Systemic lupus erythematosus ; T cells ; Ulcers</subject><ispartof>Mediators of inflammation, 2020, Vol.2020 (2020), p.1-8</ispartof><rights>Copyright © 2020 Linrong He et al.</rights><rights>COPYRIGHT 2020 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2020 Linrong He et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. http://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2020 Linrong He et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833</citedby><cites>FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833</cites><orcidid>0000-0001-5425-6157 ; 0000-0002-9044-9340 ; 0000-0002-4616-9376</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2431749557/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2431749557?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32774147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Guan, Qingdong</contributor><contributor>Qingdong Guan</contributor><creatorcontrib>Wang, Guochun</creatorcontrib><creatorcontrib>Li, Sizhao</creatorcontrib><creatorcontrib>Ge, Yongpeng</creatorcontrib><creatorcontrib>Liu, Xia</creatorcontrib><creatorcontrib>Shu, Xiaoming</creatorcontrib><creatorcontrib>He, Linrong</creatorcontrib><creatorcontrib>Lu, Xin</creatorcontrib><title>Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity</title><title>Mediators of inflammation</title><addtitle>Mediators Inflamm</addtitle><description>Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P&lt;0.001), while there was no significant difference between IMNM and HCs. There were also no significant differences of sIL-2R levels in DM, SLE, and RA. Importantly, serum sIL-2R levels were significantly higher in treatment-naïve or active DM patients than those that are not (1100.9±550.4 U/ml vs. 615.6±330.4 U/ml, P=0.006; 808.8±421.6 U/ml vs. 339.8±103.4 U/ml, P&lt;0.001). DM patients with skin ulcers had significantly higher sIL-2R levels than those without (889.3±509.9 U/ml vs. 640.0±368.7 U/ml, P=0.023). Cross-sectional analysis in DM showed that sIL-2R levels positively correlated with CK, ESR, CRP, ferritin, physician VAS, and MYOACT scores (rho=0.278, rho=0.474, rho=0.469, rho=0.454, r=0.646, and r=0.600, respectively; all P&lt;0.05), negatively correlated with T cell counts and MMT8 scores (r=−0.380, P=0.002; rho=−0.394, P=0.001). Follow-up study showed that changes in sIL-2R levels after treatment correlated with changes in physician VAS and MYOACT scores (r=0.823 and r=0.695, respectively; all P&lt;0.01). Conclusion. Serum sIL-2R levels were elevated in DM but not in IMNM. Serum sIL-2R could act as a disease activity marker and be associated with ulcerative skin lesions in DM.</description><subject>Adult</subject><subject>Age</subject><subject>Arthritis, Rheumatoid - blood</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - blood</subject><subject>Biomarkers - blood</subject><subject>Blood tests</subject><subject>Clinical medicine</subject><subject>Comparative analysis</subject><subject>Dermatomyositis</subject><subject>Dermatomyositis - blood</subject><subject>Dermatomyositis - pathology</subject><subject>Disease</subject><subject>Electronic medical records</subject><subject>Ferritin</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammatory diseases</subject><subject>Interleukin 2</subject><subject>Interleukin 2 receptors</subject><subject>Interleukins</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Musculoskeletal diseases</subject><subject>Myopathy</subject><subject>Myositis</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Receptors, Interleukin-2 - blood</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatoid factor</subject><subject>Skin</subject><subject>Skin diseases</subject><subject>Skin lesions</subject><subject>Skin Ulcer - blood</subject><subject>Skin Ulcer - pathology</subject><subject>Somatotropin</subject><subject>Studies</subject><subject>Systemic lupus erythematosus</subject><subject>T cells</subject><subject>Ulcers</subject><issn>0962-9351</issn><issn>1466-1861</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkktvEzEURkcIRENhxxqNxAYJpvVr_GCBFLU8IkVConRtPJ47icPMONhOq_x7HBJaglggLyzZ5x7rXn9F8RyjM4zr-pwggs45YRRh9aCYYMZ5hSXHD4sJUpxUitb4pHgS4wohVDMmHxcnlAjBMBOT4tuV7zdND-VsXpHyC1hYJx9KN5aXEAaT_LD10SUX35azFMtpjN46k5wfY3nr0rK8-p7Z695CiKUZ2_LSRTARyqlN7sal7dPiUWf6CM8O-2lx_eH914tP1fzzx9nFdF5ZjliqAHGDOioVkkopENBQ2cmGCsJwg6zFiDegQNqWdVbVDTHGMpwpLLiwktLTYrb3tt6s9Dq4wYSt9sbpXwc-LLQJydkeNDLWWFqThtYda6VtCLWNbQUxwJFsRHa927vWm2aA1sKYgumPpMc3o1vqhb_RgiGBMMuCVwdB8D82EJMeXLTQ92YEv4k6_xaRXCBWZ_TlX-jKb8KYR7WjsGCqrsU9tTC5ATd2Pr9rd1I95TRPjBG5c539g8qrhcFZP0Ln8vlRwZt9gQ0-xgDdXY8Y6V269C5d-pCujL_4cy538O84ZeD1Hli6sTW37j91kBnozD2NFZaC0Z9yQ9-M</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Wang, Guochun</creator><creator>Li, Sizhao</creator><creator>Ge, Yongpeng</creator><creator>Liu, Xia</creator><creator>Shu, Xiaoming</creator><creator>He, Linrong</creator><creator>Lu, Xin</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5425-6157</orcidid><orcidid>https://orcid.org/0000-0002-9044-9340</orcidid><orcidid>https://orcid.org/0000-0002-4616-9376</orcidid></search><sort><creationdate>2020</creationdate><title>Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity</title><author>Wang, Guochun ; Li, Sizhao ; Ge, Yongpeng ; Liu, Xia ; Shu, Xiaoming ; He, Linrong ; Lu, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Age</topic><topic>Arthritis, Rheumatoid - blood</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - blood</topic><topic>Biomarkers - blood</topic><topic>Blood tests</topic><topic>Clinical medicine</topic><topic>Comparative analysis</topic><topic>Dermatomyositis</topic><topic>Dermatomyositis - blood</topic><topic>Dermatomyositis - pathology</topic><topic>Disease</topic><topic>Electronic medical records</topic><topic>Ferritin</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammatory diseases</topic><topic>Interleukin 2</topic><topic>Interleukin 2 receptors</topic><topic>Interleukins</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Musculoskeletal diseases</topic><topic>Myopathy</topic><topic>Myositis</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Receptors, Interleukin-2 - blood</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatoid factor</topic><topic>Skin</topic><topic>Skin diseases</topic><topic>Skin lesions</topic><topic>Skin Ulcer - blood</topic><topic>Skin Ulcer - pathology</topic><topic>Somatotropin</topic><topic>Studies</topic><topic>Systemic lupus erythematosus</topic><topic>T cells</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Guochun</creatorcontrib><creatorcontrib>Li, Sizhao</creatorcontrib><creatorcontrib>Ge, Yongpeng</creatorcontrib><creatorcontrib>Liu, Xia</creatorcontrib><creatorcontrib>Shu, Xiaoming</creatorcontrib><creatorcontrib>He, Linrong</creatorcontrib><creatorcontrib>Lu, Xin</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Mediators of inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Guochun</au><au>Li, Sizhao</au><au>Ge, Yongpeng</au><au>Liu, Xia</au><au>Shu, Xiaoming</au><au>He, Linrong</au><au>Lu, Xin</au><au>Guan, Qingdong</au><au>Qingdong Guan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity</atitle><jtitle>Mediators of inflammation</jtitle><addtitle>Mediators Inflamm</addtitle><date>2020</date><risdate>2020</risdate><volume>2020</volume><issue>2020</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>0962-9351</issn><eissn>1466-1861</eissn><abstract>Objective. To investigate the role of soluble interleukin-2R (sIL-2R) in idiopathic inflammatory myopathies (IIM). Methods. Serum sIL-2R levels were measured in 74 dermatomyositis (DM), 16 immune-mediated necrotizing myopathy (IMNM), 24 rheumatoid arthritis (RA), 20 systemic lupus erythematosus (SLE), and 20 healthy controls (HCs) by chemiluminescent immunometric assay. Clinical features and laboratory data were collected from electronic medical record. Disease activity was evaluated by using physician global disease activity and myositis disease activity assessment visual analog scale (MYOACT) on admission. 20 DM patients were followed. Serum sIL-2R levels were analyzed and compared with clinical features, laboratory data, and measures of disease activity. Results. Serum sIL-2R levels were significantly higher in DM patients than in IMNM patients and HCs (648.8±433.1 U/ml vs. 352.3±126.0 U/ml and 648.8±433.1 U/ml vs. 285.8±101.9 U/ml, respectively; all P&lt;0.001), while there was no significant difference between IMNM and HCs. There were also no significant differences of sIL-2R levels in DM, SLE, and RA. Importantly, serum sIL-2R levels were significantly higher in treatment-naïve or active DM patients than those that are not (1100.9±550.4 U/ml vs. 615.6±330.4 U/ml, P=0.006; 808.8±421.6 U/ml vs. 339.8±103.4 U/ml, P&lt;0.001). DM patients with skin ulcers had significantly higher sIL-2R levels than those without (889.3±509.9 U/ml vs. 640.0±368.7 U/ml, P=0.023). Cross-sectional analysis in DM showed that sIL-2R levels positively correlated with CK, ESR, CRP, ferritin, physician VAS, and MYOACT scores (rho=0.278, rho=0.474, rho=0.469, rho=0.454, r=0.646, and r=0.600, respectively; all P&lt;0.05), negatively correlated with T cell counts and MMT8 scores (r=−0.380, P=0.002; rho=−0.394, P=0.001). Follow-up study showed that changes in sIL-2R levels after treatment correlated with changes in physician VAS and MYOACT scores (r=0.823 and r=0.695, respectively; all P&lt;0.01). Conclusion. Serum sIL-2R levels were elevated in DM but not in IMNM. Serum sIL-2R could act as a disease activity marker and be associated with ulcerative skin lesions in DM.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>32774147</pmid><doi>10.1155/2020/6243019</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-5425-6157</orcidid><orcidid>https://orcid.org/0000-0002-9044-9340</orcidid><orcidid>https://orcid.org/0000-0002-4616-9376</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0962-9351
ispartof Mediators of inflammation, 2020, Vol.2020 (2020), p.1-8
issn 0962-9351
1466-1861
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0acac352b35f4d8cb23cbcd72ae608b7
source Open Access: Wiley-Blackwell Open Access Journals; NCBI_PubMed Central（免费）; ProQuest - Publicly Available Content Database
subjects Adult
Age
Arthritis, Rheumatoid - blood
Autoimmune diseases
Autoimmune Diseases - blood
Biomarkers - blood
Blood tests
Clinical medicine
Comparative analysis
Dermatomyositis
Dermatomyositis - blood
Dermatomyositis - pathology
Disease
Electronic medical records
Ferritin
Humans
Inflammation
Inflammatory diseases
Interleukin 2
Interleukin 2 receptors
Interleukins
Laboratories
Lymphocytes
Lymphocytes T
Male
Medical prognosis
Middle Aged
Musculoskeletal diseases
Myopathy
Myositis
Pathogenesis
Patients
Receptors, Interleukin-2 - blood
Rheumatoid arthritis
Rheumatoid factor
Skin
Skin diseases
Skin lesions
Skin Ulcer - blood
Skin Ulcer - pathology
Somatotropin
Studies
Systemic lupus erythematosus
T cells
Ulcers
title Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A55%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20IL-2%20Receptor%20in%20Dermatomyositis:%20Its%20Associations%20with%20Skin%20Ulcers%20and%20Disease%20Activity&rft.jtitle=Mediators%20of%20inflammation&rft.au=Wang,%20Guochun&rft.date=2020&rft.volume=2020&rft.issue=2020&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=0962-9351&rft.eissn=1466-1861&rft_id=info:doi/10.1155/2020/6243019&rft_dat=%3Cgale_doaj_%3EA639994285%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c604t-e06a0f38908999e7eb38f8b37241b0cc106be9e8cd4fc95b2aac41eb31767c833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2431749557&rft_id=info:pmid/32774147&rft_galeid=A639994285&rfr_iscdi=true